Edward N. Schmidt

This paper discovers non-carbohydrate inhibitors of Siglec-7:GD3 interactions using BiGEL libraries and validates their potency through SPR, ELISA, and NMR.

This study identifies Siglec-G as a checkpoint receptor on B cells that limits germinal center (GC) response by modulating T cell help during positive selection.

This study investigates Siglec-6's binding mechanism to gangliosides, showing it relies on both conserved and membrane-associated residues for effective recognition.

This study identifies that Siglec-7 and -15 recognize repeated clustered sulfo-sialo O-glycan motifs on specific O-glycoproteins, enhancing selectivity through multivalent interactions.

The paper develops Siglec-liposomes to detect Siglec ligands and modulate immune cell function, showing they enhance T cell proliferation.

This study edits the CD33 epitope in cord blood HSPCs to reduce toxicity from CD33-targeted therapies while maintaining anti-leukemic efficacy.

This study characterizes T cell glycosylation patterns across mouse and human tissues, revealing species-specific differences in glycan profiles and dynamics.

This study identifies key residues in Siglec-10 involved in ligand recognition and shows that antibody blockade can restore CAR-T cell cytotoxicity.